128 related articles for article (PubMed ID: 19480240)
1. Expression of secreted frizzled-related protein 4 (SFRP4) in primary serous ovarian tumours.
Drake J; Shearwood AM; White J; Friis R; Zeps N; Charles A; Dharmarajan A
Eur J Gynaecol Oncol; 2009; 30(2):133-41. PubMed ID: 19480240
[TBL] [Abstract][Full Text] [Related]
2. Secreted frizzled-related protein 4 expression is positively associated with responsiveness to cisplatin of ovarian cancer cell lines in vitro and with lower tumour grade in mucinous ovarian cancers.
Saran U; Arfuso F; Zeps N; Dharmarajan A
BMC Cell Biol; 2012 Oct; 13():25. PubMed ID: 23039795
[TBL] [Abstract][Full Text] [Related]
3. Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients.
Jacob F; Ukegjini K; Nixdorf S; Ford CE; Olivier J; Caduff R; Scurry JP; Guertler R; Hornung D; Mueller R; Fink DA; Hacker NF; Heinzelmann-Schwarz VA
PLoS One; 2012; 7(2):e31885. PubMed ID: 22363760
[TBL] [Abstract][Full Text] [Related]
4. The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells.
Ford CE; Jary E; Ma SS; Nixdorf S; Heinzelmann-Schwarz VA; Ward RL
PLoS One; 2013; 8(1):e54362. PubMed ID: 23326605
[TBL] [Abstract][Full Text] [Related]
5. Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro.
Horvath LG; Henshall SM; Kench JG; Saunders DN; Lee CS; Golovsky D; Brenner PC; O'Neill GF; Kooner R; Stricker PD; Grygiel JJ; Sutherland RL
Clin Cancer Res; 2004 Jan; 10(2):615-25. PubMed ID: 14760084
[TBL] [Abstract][Full Text] [Related]
6. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
[TBL] [Abstract][Full Text] [Related]
7. TET1 inhibits EMT of ovarian cancer cells through activating Wnt/β-catenin signaling inhibitors DKK1 and SFRP2.
Duan H; Yan Z; Chen W; Wu Y; Han J; Guo H; Qiao J
Gynecol Oncol; 2017 Nov; 147(2):408-417. PubMed ID: 28851501
[TBL] [Abstract][Full Text] [Related]
8. Loss of beta-catenin is associated with poor survival in ovarian carcinomas.
Faleiro-Rodrigues C; Macedo-Pinto I; Pereira D; Lopes CS
Int J Gynecol Pathol; 2004 Oct; 23(4):337-46. PubMed ID: 15381903
[TBL] [Abstract][Full Text] [Related]
9. Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours.
Wang Y; Hewitt SM; Liu S; Zhou X; Zhu H; Zhou C; Zhang G; Quan L; Bai J; Xu N
Br J Cancer; 2006 Mar; 94(5):686-91. PubMed ID: 16479254
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
[TBL] [Abstract][Full Text] [Related]
11. Placental expression of secreted frizzled related protein-4 in the rat and the impact of glucocorticoid-induced fetal and placental growth restriction.
Hewitt DP; Mark PJ; Dharmarajan AM; Waddell BJ
Biol Reprod; 2006 Jul; 75(1):75-81. PubMed ID: 16540541
[TBL] [Abstract][Full Text] [Related]
12. Secreted frizzled-related protein 4 and its implications in cancer and apoptosis.
Pohl S; Scott R; Arfuso F; Perumal V; Dharmarajan A
Tumour Biol; 2015 Jan; 36(1):143-52. PubMed ID: 25501511
[TBL] [Abstract][Full Text] [Related]
13. Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells.
He B; Lee AY; Dadfarmay S; You L; Xu Z; Reguart N; Mazieres J; Mikami I; McCormick F; Jablons DM
Cancer Res; 2005 Feb; 65(3):743-8. PubMed ID: 15705870
[TBL] [Abstract][Full Text] [Related]
14. Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells.
Carmon KS; Loose DS
Mol Cancer Res; 2008 Jun; 6(6):1017-28. PubMed ID: 18567805
[TBL] [Abstract][Full Text] [Related]
15. Secreted Frizzled-related protein 4 (sFRP4) chemo-sensitizes cancer stem cells derived from human breast, prostate, and ovary tumor cell lines.
Deshmukh A; Kumar S; Arfuso F; Newsholme P; Dharmarajan A
Sci Rep; 2017 May; 7(1):2256. PubMed ID: 28536422
[TBL] [Abstract][Full Text] [Related]
16. Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer.
Kwon M; Kim JH; Rybak Y; Luna A; Choi CH; Chung JY; Hewitt SM; Adem A; Tubridy E; Lin J; Libutti SK
Oncotarget; 2016 Nov; 7(47):77052-77070. PubMed ID: 27776341
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic demethylation of sFRPs, with emphasis on sFRP4 activation, leading to Wnt signalling suppression and histone modifications in breast, prostate, and ovary cancer stem cells.
Deshmukh A; Arfuso F; Newsholme P; Dharmarajan A
Int J Biochem Cell Biol; 2019 Apr; 109():23-32. PubMed ID: 30710752
[TBL] [Abstract][Full Text] [Related]
18. Short peptide domains of the Wnt inhibitor sFRP4 target ovarian cancer stem cells by neutralizing the Wnt β-catenin pathway, disrupting the interaction between β-catenin and CD24 and suppressing autophagy.
Sundaram SM; Varier L; Fathima KZ; Dharmarajan A; Warrier S
Life Sci; 2023 Mar; 316():121384. PubMed ID: 36646377
[TBL] [Abstract][Full Text] [Related]
19. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
Bachmann IM; Straume O; Puntervoll HE; Kalvenes MB; Akslen LA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8606-14. PubMed ID: 16361544
[TBL] [Abstract][Full Text] [Related]
20. Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis.
Surendran K; Schiavi S; Hruska KA
J Am Soc Nephrol; 2005 Aug; 16(8):2373-84. PubMed ID: 15944336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
